News articles about DBV Technologies (NASDAQ:DBVT) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. DBV Technologies earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.2817484596516 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
A number of research firms have recently weighed in on DBVT. BidaskClub upgraded DBV Technologies from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 16th. ValuEngine upgraded DBV Technologies from a “strong sell” rating to a “sell” rating in a research report on Monday, April 2nd. Zacks Investment Research downgraded DBV Technologies from a “buy” rating to a “hold” rating in a research report on Monday, April 2nd. Deutsche Bank set a $33.00 target price on DBV Technologies and gave the company a “buy” rating in a research report on Tuesday, March 27th. Finally, HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a research report on Thursday, March 15th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the stock. DBV Technologies has a consensus rating of “Hold” and a consensus price target of $46.00.
NASDAQ:DBVT opened at $24.68 on Monday. The firm has a market cap of $1.41 billion, a PE ratio of -7.32 and a beta of 0.98. The company has a quick ratio of 4.37, a current ratio of 4.37 and a debt-to-equity ratio of 0.01. DBV Technologies has a fifty-two week low of $20.08 and a fifty-two week high of $50.57.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.